Back to discover
Drug

Faricimab

Approved · EMA
ClassVascular endothelial growth factor A inhibitorEmerging researchLate-stage development

Also known as Vabysmo.

RxNorm2591519ChEMBLCHEMBL4297750ATCS01LA09UNIIQC4F7FKK7I
3
Research papers
17
Active clinical trials
2
Protein targets
1
Regulatory events
Latest activity
beta

Recent clinical, regulatory, research and industry developments relating to this drug.

A Randomized Clinical Trial Evaluating Combination Faricimab + PRP vs. Vitrectomy + Endolaser for Treatment of Proliferative Diabetic Retinopathy

Clinical trial2026-07-16Results expected Q3 2031 · ClinicalTrials.gov

A Prospective Longitudinal Analysis of Faricimab (Vabysmo 6mg) For Choroidal Neovascularization in Presumed Ocular Histoplasmosis Syndrome [PLANE Study]

Clinical trial2026-07-10Results expected Q2 2028 · ClinicalTrials.gov

A Randomized, Double-Masked, Sham-Controlled Clinical Trial of Intravitreal Faricimab for Chronic Central Serous Chorioretinopathy With or Without Secondary Macular Neovascularization: Study Protocol for a Randomised, Double-Masked Trial

Clinical trial2026-07-02Results expected Q3 2029 · ClinicalTrials.gov

Ollin hauls in $330M to enlist Vabysmo challenger in phase 3 eye disease gauntlet

Clinical trial2026-06-23Trial news · Fierce Biotech

A Phase I/II Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of RO7446603 Administered Alone or in Combination With Aflibercept or Faricimab in Patients With Diabetic Macular Edema

Clinical trial2026-06-19Completed · ClinicalTrials.gov

A Phase I, Multicenter, Open-Label, Multiple-Ascending Dose Study of the Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of RO7823653 Administered by Intravitreal Injection as Monotherapy and in Combination With Faricimab in Patients With Diabetic Macular Edema

Clinical trial2026-06-18Results expected Q4 2028 · ClinicalTrials.gov

A Trial Evaluating Intravitreal Faricimab (6.0 mg) Injections or Fluocinolone Acetonide (0.19 mg Intravitreal Implants vs Observation for Prevention of Visual Acuity Loss Due to Radiation Retinopathy

Clinical trial2026-06-15Results expected Q4 2029 · ClinicalTrials.gov

An Exploratory, Prospective, Multi-Center, Open-Label, Single-Arm, Interventional, Phase IIB Study to Investigate Aqueous Humor and Multimodal Imaging Biomarkers in Treatment-Naïve Patients With Diabetic Macular Edema Treated With Faricimab (RO6867461) - ALTIMETER STUDY

Clinical trial2026-06-15Results posted · ClinicalTrials.gov

Aqueous Humor Biomarkers, Efficacy, and Safety in Patients with Naïve Diabetic Macular Edema Treated with Faricimab: The ALTIMETER Study.

Research2026-02-26Ophthalmology science

Four-Year Outcomes of Faricimab in Diabetic Macular Edema: Results from the RHONE-X Extension Trial.

Research2026-01-12Ophthalmology

Approval: Vabysmo (EMA)

Regulatory2022-09-15EMA

Efficacy, durability, and safety of intravitreal faricimab up to every 16 weeks for neovascular age-related macular degeneration (TENAYA and LUCERNE): two randomised, double-masked, phase 3, non-inferiority trials.

Research2022-01-24Lancet (London, England)

Profile

Identifiers & mechanism

Canonical identifiers, marketed brand names and mechanism, resolved across RxNorm, ChEMBL and ATC.

Canonical name
Faricimab
Aliases & brands
Vabysmo
RxNorm CUI
2591519
ChEMBL ID
CHEMBL4297750
ATC codes
S01LA09
UNII
QC4F7FKK7I
Primary mechanism
Vascular endothelial growth factor A inhibitor
Regulatory jurisdictions
ema

Pharmacology & targets

2 targets

Known molecular targets and mechanisms supported by curated pharmacology databases.

Vascular endothelial growth factor A, long form
VEGFA · P15692
INHIBITORVascular endothelial growth factor A inhibitor
Angiopoietin-2
ANGPT2 · O15123
INHIBITORAngiopoietin-2 inhibitor

Regulatory timeline

1 event

The complete regulatory record, grouped by authority — approvals, safety advisories and label changes. Each authority shows its most recent events; expand one to read its full history.

Earliest approval
2022-09-15
Latest approval
2022-09-15
Authorities
EMA
Total events
1
emaEuropean Medicines Agency· 1 event
2022-09-15Approval
Approval: Vabysmo (EMA)
Indication: Vabysmo is indicated for the treatment of adult patients with: neovascular (wet) age-related macular degeneration (nAMD), visual impairment due to diabetic macular oedema (DME),… Show full indication

Vabysmo is indicated for the treatment of adult patients with: neovascular (wet) age-related macular degeneration (nAMD), visual impairment due to diabetic macular oedema (DME), visual impairment due to macular oedema secondary to retinal vein occlusion (branch RVO or central RVO).

Evidence ↗

Contains information from the European Medicines Agency (European Medicines Agency), © EMA, reused under CC BY 4.0.

Clinical trials

36 trials

The current development programme across all trial phases — status mix, phase distribution and the late-stage studies shaping the evidence base.

Development programme
CLINICALTRIALS.GOV · LIVE REGISTRY
36
registered trials across all phases
LATEST COMPLETION 2026
17
Active studies
13
Recruiting
25
Late-stage (III+)
18
Completed
1
Discontinued
PHASE DISTRIBUTIONn = 36
Phase 12Phase 1 / 21Phase 28Phase 2 / 31Phase 312Phase 49Phase N / A3

Late-stage studies

Phase III+ trials still open or recently active — where late-stage evidence is being generated.

A Phase IV, Prospective, Open-label, Single-arm Clinical Trial to Evaluate the Efficacy of Faricimab and Biomarker Assessment in Patients With Neovascular Age-related Macular Degeneration

Not yet recruitingPH IVJunyeop Leen=642028

A Phase IV, Multicentre, Open-label, Single-arm Study to Investigate the Efficacy, Safety and Durability of Faricimab (RO6867461) in Caucasian Patients With Polypoidal Choroidal Vasculopathy

RecruitingPH IVAssociation for Innovation and Biomedical Research on Light and Imagen=1202028

A Prospective Longitudinal Analysis of Faricimab (Vabysmo 6mg) For Choroidal Neovascularization in Presumed Ocular Histoplasmosis Syndrome [PLANE Study]

RecruitingPH IVCincinnati Eye Institute, Southwest Ohion=252028

A Randomized, Double-masked, Sham-controlled Study to Evaluate the Efficacy of Peri-operative Farcimab in Patients With Non-clearing Vitreous Hemorrhage Secondary to Proliferative Diabetic Retinopathy

Enrolling by invitationPH IVUniversity of Colorado, Denvern=1002028

A Phase IIIb/IV, Multicenter, Randomized, Open-Label, Two-Arm Study to Investigate the Efficacy, Safety, and Durability of Faricimab Administered up to Every 24 Weeks in Patients With Neovascular Age-Related Macular Degeneration

Active, not recruitingPH IVHoffmann-La Rochen=2742027

Recent completions

Trials that read out recently, adding to the completed evidence base.

A Phase I/II Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of RO7446603 Administered Alone or in Combination With Aflibercept or Faricimab in Patients With Diabetic Macular Edema

CompletedPH I/IIGenentech, Inc.n=3882026

A Phase III, Multicenter, Randomized, Double-Masked, Active Comparator-Controlled Study to Evaluate the Efficacy and Safety of Faricimab in Patients With Choroidal Neovascularization Secondary to Pathologic Myopia

CompletedPH IIIHoffmann-La Rochen=2802026

Faricimab for Retinal Non-Perfusion Associated With Non-Proliferative Diabetic Retinopathy: The MAGIC Phase 2, Multi-Center, Open-Label, Randomized Controlled Trial

CompletedPH IIGreater Houston Retina Researchn=1792026

A Phase 1b Study to Assess the Safety, Tolerability, Pharmacokinetics, and Exploratory Efficacy of Two Different Formulations of Intravitreal OLN324 in Adult Participants With Either Neovascular (Wet) Age-related Macular Degeneration (nAMD) or Diabetic Macular Edema (DME)

CompletedPH IOllin Biosciences, Inc.n=1642025

The Effect of Intravitreal Faricimab in Patients With Refractory Macular Edema and Refractory Age Related Macular Degeneration

CompletedPH IIUniversity of Baghdadn=432025

Effects of Anti-VEGF Agents on Angiogenic Factors in FVMs Impact of Anti-VEGF Therapy on Myofibroblast Products and Profibrotic Factors in FVMs Influence of Anti-VEGF Treatment on Pericyte Markers in FVMs

CompletedN/ABojie Hun=82025

Research activity

3 papers

Key research shaping understanding of this drug, combining the latest publications with the most influential evidence.

Publications over time
20222026
Major research themes7
Angiogenesis Inhibitors2Angiopoietin-22Antibodies, Bispecific1Diabetic Retinopathy1Macular Degeneration1Macular Edema1Vascular Endothelial Growth Factor A1
Journals, researchers & institutions
Top journals
  • Lancet (London, England)1
  • Ophthalmology1
  • Ophthalmology science1
Leading researchers
  • Gibson K2
  • Khanani AM2
  • Kotak A2
  • Lai TYY2
  • Sheth VS2
  • Abreu F1
  • Amador M1
  • Basu K1
Leading institutions
free-text, unnormalised
  • The Chinese University of Hong Kong2
  • Center of Ophthalmology1
  • Clinica Baviera1
  • Clinica de Ojos Garza Viejo1
  • Department of Ophthalmology and GRADE Reading Center1
  • Eye Clinic1

Related drugs

1 matches

Drugs sharing diseases, protein targets and literature with this one. Ranked by graph evidence (shared targets + diseases weighted above co-mentions).

Aflibercept

Acts on the same molecular target as Faricimab, with an overlapping disease area.

Shared target1 shared disease1 shared paper
References & data sources
  • RxNorm (U.S. National Library of Medicine) — drug identity
  • ChEMBL (EMBL-EBI) & UniProt — pharmacology and targets
  • Europe PMC — research literature
  • ClinicalTrials.gov — clinical trials
  • Regulatory event sources are credited in the Regulatory Timeline above.